• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 2:24:33 PM ET
    $SGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGEN alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 5 )*

                

    Seagen Inc.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    81181C104


    (CUSIP Number)

    December 31, 2020


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 81181C104

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Capital International Investors
    95-1411037
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 19,476,506
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 19,872,894
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    19,872,894 Beneficial ownership disclaimed pursuant to Rule 13d-4
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    11.0%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Seagen Inc.
    (b) Address of Issuer's Principal Executive Offices
    21823 30th Drive SE, Bothell, WA 98021
    Item 2.
    (a) Name of Person Filing
    Capital International Investors
    (b) Address of Principal Business Office or, if None, Residence
    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c) Citizenship
    N/A
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    81181C104
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    19,872,894 **
    (b) Percent of Class:
    11.0%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 19,476,506
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 19,872,894
    (iv) shared power to dispose or to direct the disposition of 0
    **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl and Capital International K.K. (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 19,872,894 shares or 11.0% of the 180,306,390 shares believed to be outstanding.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Capital International Investors
    By: /s/ Walter R. Burkley
    Date: February 16, 2021
    Name: Walter R. Burkley
    Title: Senior Vice President and Senior Counsel, Fund Business Management Group, Capital Research and Management Company

    Get the next $SGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGEN

    DatePrice TargetRatingAnalyst
    2/16/2023$140.00 → $175.00In-line → Outperform
    Evercore ISI
    2/16/2023$155.00 → $175.00Outperform → Strong Buy
    Raymond James
    2/6/2023$162.00 → $141.00Outperform → Market Perform
    SVB Securities
    11/21/2022$135.00Hold
    Truist
    10/11/2022$177.00 → $178.00Market Perform → Outperform
    BMO Capital Markets
    6/29/2022$220.00Outperform
    Raymond James
    6/24/2022$169.00Market Perform
    BMO Capital Markets
    2/16/2022$201.00 → $142.00Market Outperform
    JMP Securities
    More analyst ratings

    $SGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Pfizer Completes Acquisition of Seagen

      Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio® (avelumab) in the U.S. to the American Association for Cancer Research (AACR) Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ:SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, fo

      12/14/23 7:39:00 AM ET
      $PFE
      $SGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Update: Annual Changes to the Nasdaq-100® Index

      NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same. Information For i

      12/12/23 6:00:00 PM ET
      $NDAQ
      $PFE
      $SGEN
      $TTWO
      Investment Bankers/Brokers/Service
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seagen Appoints Sandra M. Swain, M.D., to Board of Directors

      Seagen Inc. (NASDAQ:SGEN) today announced that Sandra M. Swain, M.D., has been appointed to the company's Board of Directors. Dr. Swain has more than 30 years of breast cancer clinical research experience. She currently serves as Associate Dean for Research Development and Professor of Medicine at Georgetown University Medical Center and is the Vice President of Genetic Medicine for MedStar Health. She is also on the Conquer Cancer Foundation Board of American Society of Clinical Oncology (ASCO) and chairs the Women Who Conquer Cancer committee. "We are pleased to welcome Sandra to our Board of Directors given her extensive research and clinical trial experience, especially in HER2-positiv

      11/10/22 7:05:00 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Seagen Announces Resignation of President, Chairman & CEO Clay Siegall

      Felix Baker, Ph.D., Appointed Chair of the Board Board Begins Search for New CEO Roger Dansey, M.D., Chief Medical Officer, Remains Interim CEO Seagen Inc. (NASDAQ:SGEN) today announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors. Felix J. Baker, Ph.D., formerly Lead Independent Director, has been appointed Chair of the Board of Directors. Roger Dansey, M.D., Seagen's Chief Medical Officer since 2018, will continue as interim CEO until a new CEO is found. The Board had previously announced that Dr. Siegall was on a leave of absence and that it had formed a committee of independent directors

      5/16/22 6:00:00 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGEN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Seagen Inc.

      15-12G - Seagen Inc. (0001060736) (Filer)

      12/26/23 6:12:25 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Seagen Inc.

      S-8 POS - Seagen Inc. (0001060736) (Filer)

      12/14/23 8:47:48 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Seagen Inc.

      S-8 POS - Seagen Inc. (0001060736) (Filer)

      12/14/23 8:46:25 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)

      4 - Seagen Inc. (0001060736) (Issuer)

      12/18/23 6:46:48 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)

      4 - Seagen Inc. (0001060736) (Issuer)

      12/15/23 6:55:41 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)

      4 - Seagen Inc. (0001060736) (Issuer)

      12/15/23 6:46:58 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Seagen Inc. (Amendment)

      SC 13D/A - Seagen Inc. (0001060736) (Subject)

      12/18/23 5:25:33 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Seagen Inc. (Amendment)

      SC 13G/A - Seagen Inc. (0001060736) (Subject)

      6/9/23 3:48:51 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Seagen Inc. (Amendment)

      SC 13D/A - Seagen Inc. (0001060736) (Subject)

      5/3/23 4:15:52 PM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Seagen upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Seagen from In-line to Outperform and set a new price target of $175.00 from $140.00 previously

      2/16/23 7:26:41 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Seagen upgraded by Raymond James with a new price target

      Raymond James upgraded Seagen from Outperform to Strong Buy and set a new price target of $175.00 from $155.00 previously

      2/16/23 6:40:35 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Seagen downgraded by SVB Securities with a new price target

      SVB Securities downgraded Seagen from Outperform to Market Perform and set a new price target of $141.00 from $162.00 previously

      2/6/23 7:35:55 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGEN
    Financials

    Live finance-specific insights

    See more
    • Update: Annual Changes to the Nasdaq-100® Index

      NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same. Information For i

      12/12/23 6:00:00 PM ET
      $NDAQ
      $PFE
      $SGEN
      $TTWO
      Investment Bankers/Brokers/Service
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

      Expects to close Seagen acquisition on December 14, 2023 Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution Pfizer to host analyst and investor call at 8:30 am EST on Wednesday, December 13, 2023, to discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance Pfizer Inc. (NYSE:PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer's pending acquisition of Seagen Inc. (NASDAQ:SGEN). Pfizer and Seagen have now received all required regulatory approvals to complete

      12/12/23 6:45:00 AM ET
      $PFE
      $SGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

      -Record Net Product Sales of $571 Million in 3Q23, a 33% Increase Over 3Q22, Primarily Driven by PADCEV® First-Line Launch- -PADCEV with Keytruda® Potentially Practice Changing for First-Line Metastatic Urothelial Cancer after EV-302 Trial Demonstrates Near Doubling of Median Overall Survival- -Proposed Pfizer Transaction On-Track and Anticipated to Close in Late-2023 or Early-2024, Subject to Closing Conditions, with Ongoing FTC Review and Recent EC Approval- Seagen Inc. (NASDAQ:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023. David Epstein, Chief Executive Officer of Seagen said, "Seagen continues to build momentum in 2

      11/1/23 8:00:00 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care